Puma says cancer drug meets trial goal, shares soar

(Reuters) – Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Puma said on Tuesday it plans to file for marketing approval of neratinib, code named PB272, in the first half of 2015. Adjuvant treatment with the drug showed a statistically significant improvement in disease-free survival of 33 percent versus patients on placebo, according to trial data. Adjuvant treatment, or additional treatment, is given after the primary treatment.